The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

Not yet recruiting

• Conditions: T-NK Cell Lymphoma

• Registration Number: NCT06747299
• Lead Sponsor: Ruijin Hospital

Brief Summary

Based on the PET/CT imaging data of patients with T-NK cell lymphoma, machine learning and deep learning methods are used to extract imaging features, establish a T-NK cell lymphoma prediction model, and provide more scientific and accurate prognosis prediction for the clinic.

Detailed Description

This study adopts a multicenter retrospective cohort study design，we provided PET/CT of 200 patients with T-NK cell lymphoma as an external validation set for model validation.

Study Timeline

• Status Verified: 2024-09
• Study First Submitted: 2024-12-18
• Study First Submitted QC: 2024-12-18
• Last Update Submitted: 2024-12-18
• Study First Posted: 2024-12-24
• Last Update Posted: 2024-12-24
• Study Start: 2025-01-01
• Primary Completion: 2027-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Pathological histology confirmed as T-NK Cell Lymphoma; 2.18F-FDG PET/CT examination before treatment; 3. Using modern best practice treatment options; 4. Complete clinicopathological and follow-up data were obtained.

Exclusion Criteria

1. The patient had previously received antitumor therapy;
2. The patient had a history of other tumors;
3. Incomplete clinical information or imaging data;
4. Concomitant other malignant tumors.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation the value of Artificial Intelligence-based 18F-FDG PET/CT of T-NK Cell Lymphoma	Within 1 week of enrollment and after 3 months treatment	The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma

Secondary Outcome Measures

Name	Time	Method
Progress free survival	3 years	Progress free survival
Overall survival	3 years	Overall survival

Trial Locations

Locations (1)

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine; 🇨🇳 Shanghai, Shanghai, China